Shared on 30 Oct 25
Fair value Increased 1.05%Analysts have raised their price target for Viatris from $11.88 to $12.00. They cite slightly improved revenue growth assumptions and a marginally lower discount rate in their updated models.
Shared on 15 Oct 25
Fair value Increased 3.91%Aging Populations And Asia Markets Will Unlock Future Value
Viatris's analyst price target has increased modestly from $11.43 to $11.88. Analysts cite incremental improvements in revenue growth prospects and ongoing adjustments to sector models.
Shared on 27 Aug 25
Fair value Increased 1.27%Aging Populations And Asia Markets Will Unlock Future Value
The consensus price target for Viatris has seen a marginal increase, primarily reflecting a slight improvement in revenue growth forecasts, resulting in a modest rise in fair value from $11.29 to $11.43. What's in the News FDA approved Viatris' Iron Sucrose Injection, USP, the first generic version of Venofer, for iron deficiency anemia in CKD patients, with Competitive Generic Therapy designation and 180 days of shared exclusivity.
Shared on 01 May 25
Fair value Decreased 0.89%